96 related articles for article (PubMed ID: 22000747)
1. Acute toxicity of radiochemotherapy in rectal cancer patients: a risk particularly for carriers of the TGFB1 Pro25 variant.
Schirmer MA; Mergler CP; Rave-Fränk M; Herrmann MK; Hennies S; Gaedcke J; Conradi LC; Jo P; Beissbarth T; Hess CF; Becker H; Ghadimi M; Brockmöller J; Christiansen H; Wolff HA
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):149-57. PubMed ID: 22000747
[TBL] [Abstract][Full Text] [Related]
2. High-grade acute organ toxicity during preoperative radiochemotherapy as positive predictor for complete histopathologic tumor regression in multimodal treatment of locally advanced rectal cancer.
Wolff HA; Gaedcke J; Jung K; Hermann RM; Rothe H; Schirmer M; Liersch T; Herrmann MKA; Hennies S; Rave-Fränk M; Hess CF; Christiansen H
Strahlenther Onkol; 2010 Jan; 186(1):30-35. PubMed ID: 20082185
[TBL] [Abstract][Full Text] [Related]
3. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
Liersch T; Langer C; Ghadimi BM; Kulle B; Aust DE; Baretton GB; Schwabe W; Häusler P; Becker H; Jakob C
J Clin Oncol; 2006 Sep; 24(25):4062-8. PubMed ID: 16943523
[TBL] [Abstract][Full Text] [Related]
4. X-ray cross-complementing group 1 and thymidylate synthase polymorphisms might predict response to chemoradiotherapy in rectal cancer patients.
Lamas MJ; Duran G; Gomez A; Balboa E; Anido U; Bernardez B; Rana-Diez P; Lopez R; Carracedo A; Barros F
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):138-44. PubMed ID: 21167658
[TBL] [Abstract][Full Text] [Related]
5. Dose-volume relationships between enteritis and irradiated bowel volumes during 5-fluorouracil and oxaliplatin based chemoradiotherapy in locally advanced rectal cancer.
Gunnlaugsson A; Kjellén E; Nilsson P; Bendahl PO; Willner J; Johnsson A
Acta Oncol; 2007; 46(7):937-44. PubMed ID: 17851844
[TBL] [Abstract][Full Text] [Related]
6. Clinically-staged T3N0 rectal cancer: is preoperative chemoradiotherapy the optimal treatment?
Lombardi R; Cuicchi D; Pinto C; Di Fabio F; Iacopino B; Neri S; Tardio ML; Ceccarelli C; Lecce F; Ugolini G; Pini S; Di Tullio P; Taffurelli M; Minni F; Martoni A; Cola B
Ann Surg Oncol; 2010 Mar; 17(3):838-45. PubMed ID: 20012700
[TBL] [Abstract][Full Text] [Related]
7. Potential Role of Single Nucleotide Polymorphisms of XRCC1, XRCC3, and RAD51 in Predicting Acute Toxicity in Rectal Cancer Patients Treated With Preoperative Radiochemotherapy.
Osti MF; Nicosia L; Agolli L; Gentile G; Falco T; Bracci S; Di Nardo F; Minniti G; De Sanctis V; Valeriani M; Maglio M; Borro M; Simmaco M; Enrici RM
Am J Clin Oncol; 2017 Dec; 40(6):535-542. PubMed ID: 25811296
[TBL] [Abstract][Full Text] [Related]
8. Single Nucleotide Polymorphism TGFβ1 R25P Correlates with Acute Toxicity during Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients.
Smith JJ; Wasserman I; Milgrom SA; Chow OS; Chen CT; Patil S; Goodman KA; Garcia-Aguilar J
Int J Radiat Oncol Biol Phys; 2017 Apr; 97(5):924-930. PubMed ID: 28333014
[TBL] [Abstract][Full Text] [Related]
9. Acute small-bowel toxicity during neoadjuvant combined radiochemotherapy in locally advanced rectal cancer: determination of optimal dose-volume cut-off value predicting grade 2-3 diarrhoea.
Reis T; Khazzaka E; Welzel G; Wenz F; Hofheinz RD; Mai S
Radiat Oncol; 2015 Jan; 10():30. PubMed ID: 25636703
[TBL] [Abstract][Full Text] [Related]
10. Concomitant boost radiotherapy and multidrug chemotherapy in the neoadjuvant treatment of locally advanced rectal cancer: results of a phase II study.
Caravatta L; Padula GD; Picardi V; Macchia G; Deodato F; Massaccesi M; Sofo L; Pacelli F; Rotondi F; Cecere G; Sallustio G; Di Lullo L; Piscopo A; Mignogna S; Bonomo P; Cellini N; Valentini V; Morganti AG
Acta Oncol; 2011 Nov; 50(8):1151-7. PubMed ID: 21851185
[TBL] [Abstract][Full Text] [Related]
11. Role of genetic polymorphisms in NFKB-mediated inflammatory pathways in response to primary chemoradiation therapy for rectal cancer.
Dzhugashvili M; Luengo-Gil G; García T; González-Conejero R; Conesa-Zamora P; Escolar PP; Calvo F; Vicente V; Ayala de la Peña F
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):595-602. PubMed ID: 25304949
[TBL] [Abstract][Full Text] [Related]
12. Randomized, multicenter, phase IIb study of preoperative chemoradiotherapy in T3 mid-distal rectal cancer: raltitrexed + oxaliplatin + radiotherapy versus cisplatin + 5-fluorouracil + radiotherapy.
Valentini V; Coco C; Minsky BD; Gambacorta MA; Cosimelli M; Bellavita R; Morganti AG; La Torre G; Trodella L; Genovesi D; Portaluri M; Maurizi-Enrici R; Barbera F; Maranzano E; Lupattelli M
Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):403-12. PubMed ID: 17919844
[TBL] [Abstract][Full Text] [Related]
13. Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surgery.
Toiyama Y; Inoue Y; Saigusa S; Okugawa Y; Yokoe T; Tanaka K; Miki C; Kusunoki M
Clin Oncol (R Coll Radiol); 2010 May; 22(4):272-80. PubMed ID: 20117921
[TBL] [Abstract][Full Text] [Related]
14. Volume and hormonal effects for acute side effects of rectum and bladder during conformal radiotherapy for prostate cancer.
Peeters ST; Hoogeman MS; Heemsbergen WD; Slot A; Tabak H; Koper PC; Lebesque JV
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1142-52. PubMed ID: 15939547
[TBL] [Abstract][Full Text] [Related]
15. Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: use of dose-volume constraints to achieve rectal isotoxicity.
Vargas C; Yan D; Kestin LL; Krauss D; Lockman DM; Brabbins DS; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):141-9. PubMed ID: 16111582
[TBL] [Abstract][Full Text] [Related]
16. Combination of differentiation and T stage can predict unresponsiveness to neoadjuvant therapy for rectal cancer.
Qiu HZ; Wu B; Xiao Y; Lin GL
Colorectal Dis; 2011 Dec; 13(12):1353-60. PubMed ID: 21689282
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy: polymorphisms in thymidylate synthase, epidermal growth factor receptor, GSTP1, and DNA repair genes.
Páez D; Salazar J; Paré L; Pertriz L; Targarona E; del Rio E; Barnadas A; Marcuello E; Baiget M
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1319-27. PubMed ID: 21570215
[TBL] [Abstract][Full Text] [Related]
18. Small bowel dose parameters predicting grade ≥ 3 acute toxicity in rectal cancer patients treated with neoadjuvant chemoradiation: an independent validation study comparing peritoneal space versus small bowel loop contouring techniques.
Banerjee R; Chakraborty S; Nygren I; Sinha R
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1225-31. PubMed ID: 23182394
[TBL] [Abstract][Full Text] [Related]
19. Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy.
Cecchin E; Agostini M; Pucciarelli S; De Paoli A; Canzonieri V; Sigon R; De Mattia E; Friso ML; Biason P; Visentin M; Nitti D; Toffoli G
Pharmacogenomics J; 2011 Jun; 11(3):214-26. PubMed ID: 20368715
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901.
; Ryan DP; Niedzwiecki D; Hollis D; Mediema BE; Wadler S; Tepper JE; Goldberg RM; Mayer RJ
J Clin Oncol; 2006 Jun; 24(16):2557-62. PubMed ID: 16636336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
